Loss of Transfusion Dependency Following Deferasirox Treatment of Iron Overload in a Woman with Myelofibrosis and Spherocytosis - a Case Report

Publisher： Karger

E-ISSN： 2296-5262|36|4|205-208

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.36, Iss.4, 2013-03, pp. : 205-208

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Deferasirox (Exjade®) for the Treatment of Iron Overload

By  

Acta Haematologica, Vol. 122, Iss. 2-3, 2009-11 ,pp. : 165-173

Karger

Access to resources Recommend Favorite

Transfusion Independency and Histological Remission in a Patient with Advanced Primary Myelofibrosis Receiving Iron-Chelation Therapy with Deferasirox

By  

Oncology Research and Treatment, Vol. 39, Iss. 6, 2016-05 ,pp. : 384-387

Karger

Access to resources Recommend Favorite

HJV Hemochromatosis, Iron Overload, and Hypogonadism in a Brazilian Man: Treatment with Phlebotomy and Deferasirox

By  

Acta Haematologica, Vol. 124, Iss. 4, 2010-11 ,pp. : 204-205

Karger

Access to resources Recommend Favorite

Deferasirox Treatment Improved the Hemoglobin Level and Decreased Transfusion Requirements in Four Patients with the Myelodysplastic Syndrome and Primary Myelofibrosis

By  

Acta Haematologica, Vol. 120, Iss. 2, 2008-10 ,pp. : 70-74

Karger

Access to resources Recommend Favorite

Two-Year Analysis of Efficacy and Safety of Deferasirox Treatment for Transfusional Iron Overload in Sickle Cell Anemia Patients

By  

Acta Haematologica, Vol. 128, Iss. 2, 2012-06 ,pp. : 113-118

Karger

Access to resources Recommend Favorite